| Literature DB >> 29671959 |
Adrian Post1, Isidor Minović1,2,3, Else van den Berg1, Manfred L Eggersdorfer4, Gerjan J Navis1, Johanna M Geleijnse5, Reinold O B Gans1, Harry van Goor6, Joachim Struck7, Casper F M Franssen1, Ido P Kema3, Stephan J L Bakker1,2,8.
Abstract
Inorganic sulfate is essential for normal cellular function and its homeostasis is primarily regulated in the kidneys. However, little is known about renal sulfate handling in humans and particularly in populations with impaired kidney function such as renal transplant recipients (RTR). Hence, we aimed to assess sulfate reabsorption in kidney donors and RTR. Plasma and urinary sulfate were determined in 671 RTR and in 251 kidney donors. Tubular sulfate reabsorption (TSR) was defined as filtered load minus sulfate excretion and fractional sulfate reabsorption (FSR) was defined as 1-fractional excretion. Linear regression analyses were employed to explore associations of FSR with baseline parameters and to identify the determinants of FSR in RTR. Compared to kidney donors, RTR had significantly lower TSR (15.2 [11.2-19.5] vs. 20.3 [16.7-26.3] μmol/min), and lower FSR (0.56 [0.48-0.64] vs. 0.64 [0.57-0.69]) (all P < 0.001). Kidney donation reduced both TSR and FSR by circa 50% and 25% respectively (both P < 0.001). In RTR and donors, both TSR and FSR associated positively with renal function. In RTR, FSR was independently associated with urinary thiosulfate (β = -0.18; P = 0.002), growth hormone (β = 0.12; P = 0.007), the intakes of alcohol (β = -0.14; P = 0.002), methionine (β = -0.34; P < 0.001), cysteine (β = -0.41; P < 0.001), and vitamin D (β = -0.14; P = 0.009). In conclusion, TSR and FSR are lower in RTR compared to kidney donors and both associated with renal function. Additionally, FSR is determined by various dietary and metabolic factors. Future research should determine the mechanisms behind sulfate handling in humans and the prognostic value of renal sulfate reabsorption in RTR.Entities:
Keywords: Kidney donation; renal sulfate handling; renal transplant recipients; sulfate reabsorption
Mesh:
Substances:
Year: 2018 PMID: 29671959 PMCID: PMC5907819 DOI: 10.14814/phy2.13670
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Figure 1Plasma sulfate concentrations, tubular sulfate reabsorption and fractional sulfate reabsorption in 251 kidney donors before kidney donation and in 671 renal transplant recipients. RTR, renal transplant recipients.
Sulfate parameters in kidney donors before and after kidney donation
| Pre‐donation | Post‐donation |
| |
|---|---|---|---|
| Plasma sulfate (mmol/L) | 0.27 [0.24–0.31] | 0.29 [0.26–0.32] | <0.001 |
| Sulfate excretion (mmol/24 h) | 17.7 [14.4–20.8] | 17.2 [12.2–22.0] | <0.001 |
| GFR (mL/min/1.73 m2) | 113 ± 22 | 74 ± 13 | <0.001 |
| Sulfate clearance (mL/min) | 43.9 [35.9–53.4] | 39.3 [31.2–50.2] | <0.001 |
| Fractional sulfate excretion (%) | 40 [33–46] | 55 [47–68] | <0.001 |
| Filtered sulfate load ( | 30.3 [26.3–36.0] | 22.1 [189–25.0] | <0.001 |
| Tubular sulfate reabsorption ( | 18.8 ± 6.3 | 9.3 ± 4.5 | <0.001 |
| Fractional sulfate reabsorption (%) | 60 [54–67] | 45 [32–53] | <0.001 |
| Tubular potassium reabsorption ( | 361 [314–437] | 231 [201–272] | <0.001 |
| Fractional potassium reabsorption (%) | 0.86 [0.83–0.89] | 0.80 [0.76–0.84] | <0.001 |
| Tubular sodium reabsorption (mmol/min) | 15.7 [13.8–18.0] | 10.2 [9.0–11.6] | <0.001 |
| Fractional sodium reabsorption (%) | 0.99 [0.99–0.99] | 0.99 [0.99–0.99] | <0.001 |
P value for difference was tested by Wilcoxon Signed‐Rank test or paired sample t‐test. Tubular and fractional sulfate reabsorption were calculated using the urinary clearance of 125I‐iothalamate method as the measured GFR.
Figure 2Tubular and fractional sulfate reabsorption before and after kidney donation in 251 kidney donors. Tubular and fractional sulfate reabsorption were calculated using the urinary clearance of 125I‐Iothalamate method as GFR.
Baseline characteristics of renal transplant recipients presented according to gender‐stratified tertiles of fractional sulfate reabsorption
| Total cohort ( | Tertiles of FSR |
| |||
|---|---|---|---|---|---|
| I 0.04–0.54 ( | II 0.49–0.76 ( | III 0.61–0.84 ( | |||
| FSR, % | 0.56 ± 0.12 | 0.42 ± 0.09 | 0.57 ± 0.04 | 0.68 ± 0.05 | |
| Urinary sulfate, mmol/24 h | 17.6 ± 6.4 | 20.8 ± 6.4 | 17.9 ± 5.4 | 14.0 ± 4.8 | <0.001 |
| Urinary thiosulfate, | 7.1 [4.0–12.0] | 8.6 [4.4–13.2] | 7.9 [4.3–13.3] | 5.9 [3.5–9.3] | <0.001 |
| Demographics | |||||
| Age, years | 53 ± 13 | 52 ± 13 | 53 ± 13 | 54 ± 13 | 0.02 |
| Male gender, | 384 (57) | 128 (57) | 128 (57) | 128 (57) | |
| BMI, kg/m2 | 26.0 [23.3–29.3] | 25.6 [23.1–28.7] | 26.0 [23.6–29.2] | 26.5 [23.2–30.1] | 0.003 |
| Smokers, | |||||
| Never | 266 (42) | 84 (39) | 88 (42) | 94 (45) | 0.22 |
| Past | 285 (45) | 102 (48) | 101 (49) | 82 (39) | 0.09 |
| Current | 77 (12) | 25 (12) | 19 (9) | 33 (16) | 0.45 |
| Dialysis vintage, months | 24 [10–47] | 24 [9–50] | 23 [8–46] | 25 [14–50] | 0.08 |
| Time since Rtx, years | 5.4 [1.8–12.0] | 5.0 [1.3–11.3] | 6.1 [1.4–12.0] | 5.7 [2.9–12.9] | 0.06 |
| Deceased donor, | 433 (66) | 130 (60) | 142 (64) | 161 (72) | 0.003 |
| Creatinine excretion, mmol/24 h | 11.3 [9.2–14.0] | 11.5 [9.2–14.3] | 11.7 [9.6–14.1] | 11.0 [8.9–13.9] | 0.05 |
| Dietary intake | |||||
| Vegetarian, | 14 (2) | 5 (2) | 5 (3) | 4 (2) | 0.68 |
| Alcohol intake, g/d | 3.0 [0.04–11.5] | 4.6 [0.1–14.8] | 3.4 [0.2–12.5] | 1.0 [0.02–8.5] | <0.001 |
| Water intake, g/d | 2074 ± 587 | 2138 ± 599 | 2093 ± 559 | 2021 ± 719 | 0.002 |
| Bread intake, g/d | 133 ± 60 | 137 ± 65 | 132 ± 53 | 129 ± 62 | <0.001 |
| Fruit, g/d | 123 [60–232] | 135 [73–239] | 124 [66–237] | 105 [50–227] | 0.04 |
| Vegetables, g/d | 91 [51–123] | 91 [58–132] | 91 [56–1234] | 85 [46–116] | 0.35 |
| Animal protein, g/d | 53 ± 16 | 53 ± 16 | 52 ± 14 | 49 ± 15 | 0.001 |
| Vegetable protein, g/d | 31 ± 10 | 31 ± 11 | 30 ± 8 | 30 ± 11 | 0.07 |
| Methionine, mg/d | 1884 ± 5.9 | 1923 ± 495 | 1895 ± 421 | 1795 ± 496 | <0.001 |
| Cysteine, mg/d | 1190 ± 307 | 1220 ± 313 | 1191 ± 249 | 1145 ± 312 | <0.001 |
| Vitamin D intake, | 4.6 [3.4–5.9] | 4.7 [3.4–6.0] | 4.7 [3.7–5.8] | 4.4 [3.3–5.9] | 0.001 |
| Energy intake, kcal/d | 2173 ± 656 | 2174 ± 635 | 2171 ± 567 | 2159 ± 687 | 0.02 |
| Primary renal disease, | |||||
| Primary glomeruloslerosis | 192 (29) | 59 (27) | 68 (30) | 65 (29) | 0.52 |
| Glomerulonephritis | 51 (8) | 15 (7) | 18 (8) | 18 (8) | 0.54 |
| Tubulointerstitial nephritis | 77 (11) | 25 (11) | 23 (10) | 29 (13) | 0.26 |
| Polycystic kidney disease | 136 (20) | 43 (19) | 47 (21) | 45 (20) | 0.81 |
| Hypo‐ or dysplasia | 27 (4) | 10 (5) | 10 (4) | 7 (3) | 0.07 |
| Renovascular disease | 39 (6) | 18 (8) | 12 (5) | 9 (4) | 0.01 |
| Glucose homeostasis | |||||
| Diabetes, | 163 (24) | 46 (21) | 53 (24) | 64 (29) | 0.03 |
| Glucose, mmol/L | 5.3 [4.8–6.0] | 5.3 [4.8–6.0] | 5.2 [4.7–5.9] | 5.3 [4.8–6.2] | 0.85 |
| HbA1c, % | 6.0 ± 0.8 | 5.9 ± 0.8 | 6.0 ± 0.8 | 6.1 ± 0.9 | 0.74 |
| Antidiabetics, | 105 (16) | 30 (14) | 34 (15) | 41 (16) | 0.09 |
| Inflammation | |||||
| hs‐CRP, mg/L | 1.6 [0.7–4.7] | 1.5 [0.6–3.5] | 1.7 [0.8–5.3] | 1.7 [0.8–5.0] | 0.01 |
| Cardiovascular | |||||
| NT‐proBNP, ng/L | 251 [104–612] | 200 [98–615] | 235 [95–515] | 285 [119–703] | <0.001 |
| SBP, mmHg | 136 ± 17 | 135 ± 18 | 135 ± 16 | 137 ± 18 | 0.40 |
| DBP, mmHg | 83 ± 11 | 83 ± 12 | 83 ± 10 | 81 ± 10 | 0.09 |
| Antihypertensives, | 592 (88) | 188 (84) | 198 (88) | 205 (92) | 0.04 |
| Diuretic, | 245 (36) | 71 (32) | 97 (43) | 103 (46) | <0.001 |
| Potassium sparing | 4 (1) | 2 (1) | 0 (0) | 2 (1) | 0.88 |
| Loop | 138 (21) | 42 (19) | 47 (21) | 49 (22) | 0.08 |
| Thiazide | 102 (15) | 21 (9) | 43 (19) | 38 (17) | 0.11 |
| Total cholesterol, mmol/L | 5.1 ± 1.1 | 5.1 ± 1.1 | 5.2 ± 1.1 | 5.1 ± 1.2 | 0.65 |
| HDL‐cholesterol, mmol/L | 1.4 ± 0.5 | 1.4 ± 0.5 | 1.4 ± 0.5 | 1.4 ± 0.5 | 0.94 |
| LDL‐cholesterol, mmol/L | 2.9 [2.3–3.5] | 2.9 [2.4–3.5] | 3.0 [2.4–3.6] | 2.8 [2.3–3.5] | 0.54 |
| Triglycerides, mmol/L | 1.7 [1.2–2.3] | 1.7 [1.2–2.2] | 1.7 [1.2–2.3] | 1.7 [1.3–2.4] | 0.07 |
| Statins, | 350 (52) | 112 (50) | 117 (52) | 121 (54) | 0.34 |
| NSAID, | 127 (19) | 40 (18) | 45 (20) | 42 (19) | 0.74 |
| Renal function | |||||
| eGFR, mL/min/1.73 m2 | 45 ± 19 | 44 ± 18 | 47 ± 19 | 45 ± 18 | 0.59 |
| Proteinuria, ≥0.5 g/24 h, | 149 (22) | 41 (18) | 46 (21) | 62 (28) | 0.12 |
| Metabolic parameters | |||||
| Serum potassium, mmol/L | 3.98 ± 0.47 | 3.84 ± 0.46 | 3.95 ± 0.44 | 4.03 ± 0.49 | 0.20 |
| Venous pH | 7.4 ± 0.04 | 7.4 ± 0.04 | 7.4 ± 0.04 | 7.4 ± 0.04 | 0.32 |
| Venous HCO3 −, mmol/L | 24.7 ± 3.1 | 24.5 ± 2.9 | 24.9 ± 3.1 | 24.6 ± 3.2 | 0.83 |
| Net acid excretion, mEq/24 h | 61.1 ± 32.6 | 63.6 ± 34.8 | 63.0 ± 27.9 | 56.2 ± 33.8 | <0.001 |
| Liver function | |||||
| LDH, U/L | 198 [170–232] | 200 [167–233] | 197 [173–235] | 197 [170–228] | 0.42 |
| Alkaline phosphatase, U/L | 68 [54–84] | 66 [54–80] | 68 [54–85] | 69 [54–88] | 0.82 |
| Gamma‐GT, U/L | 26 [19–41] | 26 [19–43] | 26 [19–39] | 27 [19–42] | 0.40 |
| Endocrinology | |||||
| Triiodothyronine, pmol/L | 4.9 ± 0.8 | 4.9 ± 0.8 | 4.9 ± 0.9 | 4.8 ± 0.7 | 0.27 |
| Thyroxine, pmol/L | 16.1 ± 2.9 | 16.2 ± 2.6 | 16.2 ± 3.0 | 15.8 ± 3.2 | 0.24 |
| Growth hormone, ng/mL | 0.34 [0.10–1.07] | 0.27 [0.08–1.01] | 0.30 [0.09–0.87] | 0.43 [0.12–1.28] | 0.002 |
| Immunosuppression | |||||
| CNI, | 382 (57) | 121 (54) | 127 (56) | 134 (60) | 0.05 |
| Proliferation inhibitor, | 560 (83) | 188 (84) | 192 (85) | 179 (80) | 0.37 |
| Prednisolone, mg/24 h | 10.0 [7.5–10.0] | 10.0 [7.5–10.0] | 10.0 [7.5–10.0] | 10.0 [7.5–10.0] | 0.36 |
RTR, renal transplant recipients; RSR, renal sulfate reabsorption, BMI, body mass index; Rtx, renal transplantation; hs‐CRP, high‐sensitive C‐reactive protein; NT‐proBNP, N‐terminal pro‐b‐type natriuretic peptide; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; NSAID, nonsteroidal anti‐inflammatory drug; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; gamma‐GT; gamma‐glutamyl transferase; CNI, calcineurin inhibitor.
Figure 3Associations between plasma sulfate, tubular sulfate reabsorption, and fractional sulfate reabsorption in 251 kidney donors before donation and in 671 renal transplant recipients. Tubular and fractional sulfate reabsorption were calculated with creatinine clearance. Tubular sulfate reabsorption in kidney donors P effect < 0.001; P nonlineariry = 0.20; tubular sulfate reabsorption in RTR P effect < 0.001; P nonlineariry < 0.001; fractional sulfate reabsorption in kidney donors P effect = 0.05; P nonlineariry = 0.13; fractional sulfate reabsorption in RTR P effect = 0.01; P nonlineariry = 0.16.
Regression analyses with potential determinants of fractional sulfate reabsorption in renal transplant recipients
| Potential determinants | Univariable models | Multivariable model | ||
|---|---|---|---|---|
| Stand. beta |
| Stand. beta |
| |
| Plasma sulfate, mmol/L | 0.11 | 0.011 | 0.05 | 0.203 |
| Urinary thiosulfate, | −0.23 | <0.001 | −0.18 | 0.002 |
| Creatinine cleanance (mL/min) | 0.10 | 0.021 | 0.16 | <0.001 |
| Dietary intake | ||||
| Alcohol intake, g/d | −0.18 | <0.001 | −0.14 | 0.002 |
| Water intake, g/d | −0.13 | 0.002 | −0.15 | 0.003 |
| Bread intake, g/d | −0.15 | <0001 | −0.12 | 0.010 |
| Daily fruit, g/d | −0.08 | 0.056 | −0.12 | 0.005 |
| Methionine, mg/d | −0.17 | <0.001 | −0.34 | <0.001 |
| Cysteine, mg/d | −0.17 | <0.001 | −0.41 | <0.001 |
| Vitamin D intake, | −0.12 | 0.004 | −0.14 | 0.009 |
| Cardiovascular | ||||
| NSAID, | 0.02 | 0.628 | 0.01 | 0.753 |
| Serum potassium, mmol/L | 0.04 | 0.356 | 0.04 | 0.322 |
| Metabolic parameters | ||||
| Venous pH | 0.01 | 0.871 | 0.03 | 0.534 |
| Venous HCO3 −, mmol/L | 0.03 | 0.533 | 0.02 | 0.631 |
| Net acid Excretion, mEq/24 h | −0.23 | <0.001 | −0.19 | <0.001 |
| Endocrinology | ||||
| Thyroxine pmol/L | −0.05 | 0.239 | −0.07 | 0.086 |
| Triiodothyronine, pmol/L | −0.03 | 0.476 | −0.03 | 0.533 |
| Growth hormone, ng/mL | 0.14 | 0.001 | 0.11 | 0.007 |
| In men | 0.20 | <0.001 | 0.21 | <0.001 |
| In women | −0.05 | 0.475 | −0.04 | 0.599 |
FSR, fractional sulfate reabsorption; RTR, renal transplant recipients; NSAID, nonsteroidal anti‐inflammatory drug.
Adjusted for potential confounders, including age, gender, smoking, BMI, proteinuria, total energy intake and primary renal disease.